Control of N-nitrosamine impurities in drug products: Progressing the current CPCA framework and supporting the derivation of robust compound specific acceptable intakes
David J. Ponting, Robert Thomas, Joerg Schlingemann(Merck KGaA, Darmstadt (Germany)), Andrew Teasdale(AstraZeneca (United Kingdom)), James Harvey(GlaxoSmithKline (United Kingdom)), Raphael Nudelman(Applied Materials (Israel)), Stéphanie Simon(Merck KGaA, Darmstadt (Germany)), Andreas Czich(Sanofi (Germany)), Susanne Glowienke(Novartis (Switzerland)), Susan P. Felter(Procter & Gamble (United States)), G. Smith(AstraZeneca (United Kingdom))
Cited by 13
Related Papers
OxyR
|Cell|2002|474
S-nitrosylation: spectrum and specificity
|Nature Cell Biology|2001|243
Drug Insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis
|Nature Clinical Practice Rheumatology|2008|197
An Integrated in Silico 3D Model-Driven Discovery of a Novel, Potent, and Selective Amidosulfonamide 5-HT<sub>1A</sub> Agonist (PRX-00023) for the Treatment of Anxiety and Depression
|Journal of Medicinal Chemistry|2006|141
A nitric oxide processing defect of red blood cells created by hypoxia: Deficiency of S-nitrosohemoglobin in pulmonary hypertension
|Proceedings of the National Academy of Sciences|2005|132